Asian Growth Companies Insiders Are Investing In

As the Asian markets navigate a landscape of economic uncertainties and potential government stimuli, investors are keenly observing companies that demonstrate robust insider confidence. In this context, stocks with high insider ownership often signal trust in the company's growth prospects, making them an attractive consideration for those looking to capitalize on potential market opportunities.

Top 10 Growth Companies With High Insider Ownership In Asia

Name	Insider Ownership	Earnings Growth
Zhejiang Leapmotor Technology (SEHK:9863)	15.6%	60.1%
Techwing (KOSDAQ:A089030)	18.8%	68%
Sineng ElectricLtd (SZSE:300827)	36%	26.9%
Shanghai Huace Navigation Technology (SZSE:300627)	24.4%	23.5%
Schooinc (TSE:264A)	30.6%	68.9%
Samyang Foods (KOSE:A003230)	11.7%	24.3%
Oscotec (KOSDAQ:A039200)	21.1%	94.4%
Nanya New Material TechnologyLtd (SHSE:688519)	11%	63.3%
Laopu Gold (SEHK:6181)	35.5%	40.2%
Fulin Precision (SZSE:300432)	13.6%	44.2%

Click here to see the full list of 617 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.

Let's dive into some prime choices out of the screener.

Kingsoft (SEHK:3888)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Kingsoft Corporation Limited operates in the entertainment and office software and services sectors across Mainland China, Hong Kong, and internationally, with a market cap of approximately HK$47.88 billion.

Operations: The company's revenue is primarily derived from its online games and others segment, which generated CN¥5.32 billion, and its office software and services segment, contributing CN¥5.20 billion.

Insider Ownership: 19.1%

Earnings Growth Forecast: 22.4% p.a.

Kingsoft demonstrates significant growth potential with earnings expected to grow at 22.4% annually, outpacing the Hong Kong market. Despite slower revenue growth of 13.2%, it remains above the market average. The stock is trading significantly below its estimated fair value, suggesting potential upside as analysts predict a price increase of 29.3%. Recent earnings showed stable performance with Q1 revenue at CNY 2,338 million and net income nearly unchanged year-over-year at CNY 283.87 million.

• Navigate through the intricacies of Kingsoft with our comprehensive analyst estimates report here.
• Insights from our recent valuation report point to the potential undervaluation of Kingsoft shares in the market.

Beijing Fourth Paradigm Technology (SEHK:6682)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Beijing Fourth Paradigm Technology Co., Ltd. is an investment holding company that offers platform-centric artificial intelligence solutions in the People's Republic of China, with a market cap of HK$22.69 billion.

Operations: The company's revenue is derived from three main segments: Sage AI Platform (CN¥3.68 billion), Shift Intelligent Solutions (CN¥1.02 billion), and Sagegpt Aigs Services (CN¥562.50 million).

Insider Ownership: 21.5%

Earnings Growth Forecast: 96.6% p.a.

Beijing Fourth Paradigm Technology is poised for substantial growth, with earnings projected to rise 96.58% annually and revenue expected to expand at 19.1% per year, outpacing the Hong Kong market. Despite a net loss reduction from CNY 908.72 million to CNY 268.79 million in 2024, the company remains on track for profitability within three years. Recent governance changes aim to bolster corporate practices, while analysts anticipate a stock price increase of nearly 29.6%.

• Click to explore a detailed breakdown of our findings in Beijing Fourth Paradigm Technology's earnings growth report.
• Our comprehensive valuation report raises the possibility that Beijing Fourth Paradigm Technology is priced lower than what may be justified by its financials.

Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076)

Simply Wall St Growth Rating: ★★★★★★

Overview: Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. is a biomedical company focused on the research, development, production, sale, and technical service of peptides and small molecule drugs in China, with a market cap of CN¥12.41 billion.

Operations: The company generates revenue from its Specialty Chemicals segment, amounting to CN¥1.83 billion.

Insider Ownership: 15.1%

Earnings Growth Forecast: 26.7% p.a.

Jiangsu Sinopep-Allsino Biopharmaceutical is experiencing robust growth, with Q1 2025 revenue climbing to CNY 565.6 million from CNY 355.82 million a year prior and net income more than doubling to CNY 152.62 million. Earnings are forecasted to grow significantly at 26.7% annually, outpacing the Chinese market's average growth rate, while the stock trades at a substantial discount to its estimated fair value, indicating potential for future appreciation despite limited insider trading activity recently observed.

• Take a closer look at Jiangsu Sinopep-Allsino Biopharmaceutical's potential here in our earnings growth report.
• According our valuation report, there's an indication that Jiangsu Sinopep-Allsino Biopharmaceutical's share price might be on the cheaper side.

Make It Happen

• Click this link to deep-dive into the 617 companies within our Fast Growing Asian Companies With High Insider Ownership screener.
• Ready To Venture Into Other Investment Styles? Outshine the giants: these 25 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com